Accelerating success: advanced developability strategies for bioconjugates and ADCs

Live30 webinars pack the latest innovations and applications into a data-rich 30-minute session.

Gain insights into how Lonza’s Early Development Services can support the successful progression of bioconjugates - from late discovery through early preclinical development. This webinar will focus on the unique challenges associated with developing antibody–drug conjugates (ADCs) and other bioconjugate modalities, including molecule selection, developability, safety, and manufacturability at an early stage. 

Learn how Lonza’s enabling technologies and integrated developability assessments can help de‑risk your bioconjugate program, mitigate patient safety risks, and improve your likelihood of clinical success. We will also highlight how these capabilities extend across monoclonal antibodies and novel formats, ensuring a robust foundation for downstream development and scalability. 

Register to:

• Gain practical insights into overcoming developability, safety, and manufacturability challenges from late discovery through early preclinical development
• Learn strategies and enabling technologies that improve efficiency, support better early decision‑making, and reduce downstream risk, streamlining the path to IND
• Understand the advantages of partnering with a CDMO that supports the full life cycle - from late-stage discovery through clinical development and commercial manufacturing ensuring continuity and long‑term success

Yvette Stallwood, PhD

Senior Director, Head of Early Development Services at Lonza

Yvette Stallwood completed her PhD at the University of Birmingham (UK) and has a background in Virology, Cell & Molecular Biology. She joined Lonza in 2007 and is currently Head of Early Development Services and Site Head of Cambridge, UK, where she supports the development of new biotherapeutic proteins and vaccines with a particular focus on immunogenicity, manufacturability and protein expression.

Raphael Frey, PhD

Director, Commercial Development at Lonza

Raphael Frey has over 10 years’ experience working at the interface of chemistry and biology in both academia and industry. In his current role at Lonza, he is responsible for shaping innovative solutions for customers that embark on a bioconjugate development journey. Previously, Raphael worked as a project lead in process development for clinical and commercial ADC manufacturing. Raphael has a PhD in chemical biology from ETH Zürich, focusing on enzyme engineering and biocatalysis.

In 33 Days

You have registered for this webinar

Register

SPEAKERS

Yvette Stallwood, PhD

Senior Director, Head of Early Development Services at Lonza

Raphael Frey, PhD

Director, Commercial Development at Lonza

You might also like

Innovations in process development and manufacturing for scaling ADCs

E Idusogie, J Bridgewater, S Zhang

23 September 2025

Watch

Navigating TFF in small-scale GMP: Insights for advanced therapeutics

J Fåhraeus, R Pujari, M Rimmö

9 October 2025

Watch

Tools, trends, and technologies: analytical development in ADCs

L Yang, W Lee, E Dirksen et al.

16 April

Watch

Unlock advanced strategies in cell therapy analytics

S Krause, K Shum, A Chandran et al.

25 November 2025

Watch